JAK2 and myeloproliferative neoplasm: To evaluate the efficacy of cdPCR compared to qPCR in detecting the % JAK2 V617F, we analyzed peripheral blood samples from de novo MPN patients carrying the JAK2 V617F mutation without CARL and MPL mutations.